2018 BIO International Convention - Browse Agenda

All Sessions

4:00 PM–5:00 PM

Jun 4, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

AMR Industry Alliance: Forging antimicrobial R&D pacts

Room 255, Level 2

Speakers

Mr. Steve BatesCEO atBioIndustry Association

Fumie GRIEGOAssistant Director General atInternational Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

Mrs. Florence SéjournéCEO atDA VOLTERRA

11:00 AM–12:00 PM

Jun 5, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

From One Epidemic to the Next: Learning from Ebola and Zika

Room 251, Level 2

Speakers

Anita CiceroDeputy Director & COO atCenter for Health Security at Johns Hopkins Bloomberg School of Public Health

Dr. Rick BrightDeputy Assistant Secretary for Preparedness and Response, Director of Biomedical Advances Research and Development Authority atU.S. Department of Health and Human Services (HHA)

Mr. Nima FarzanCEO and President atPaxvax

Dr. Joseph KimCEO atInovio

Julia SpencerAssociate Vice President, Global Vaccines Public Policy, Partnerships, and Government Affairs atMerck & Co, Inc.

12:15 PM–1:30 PM

Jun 5, 2018

bio2018-mybio-sessionicon-supersess

Infectious Diseases & Vaccines

The Global Vaccines Business: A View from the Top

Room 253ABC, Level 2

Speakers

Stanley ErckPresident and Chief Executive Officer atNovavax

Jacqueline Keith, MA,PhDPresident atJ Keith Consulting Corp.

David LoewExecutive Vice President, Head atSanofi Pasteur

Michael NallyPresident atMerck Vaccines

Gordon NaylorPresident atSeqirus

Dr. Rajeev VenkayyaPresident, Global Vaccine Business Unit atTakeda Pharmaceutical Company Limited

1:45 PM–2:45 PM

Jun 5, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

Ensuring Our National Health Security: Strategic Initiatives in the PAHPA Reauthorization

Room 251, Level 2

Speakers

Helen BranswellInfectious Diseases and Public Health Reporter atSTAT

Rip BallouVice President and Head, Global Vaccines US R&D Center atGSK

Luciana BorioAssistant Commissioner of FDA for Counterterrorism Policy atNational Security Council

Sen. Thomas DaschleFounder and CEO atThe Daschle Group

Phillip GomezCEO atSIGA Technologies, Inc

Dr. Robert KadlecAssistant Secretary for Preparedness and Response atU.S. Department of Health and Human Services (HHS)

3:00 PM–4:00 PM

Jun 5, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

Driving R&D Innovation in Vaccines through a Robust Ecosystem

Room 251, Level 2

Speakers

Dr. Oreola Donini, PhDChief Scientific Officer atSoligenix, Inc.

Emmanuel HanonSenior Vice President, Head of Vaccines Research and Development atGlaxoSmithKline

Wayne Koff, PhDPresident and CEO atHuman Vaccines Project

Ofer Levy, PhD,MDDirector, Precision Vaccines Program; Associate Professor atBoston Children's Hospital; Harvard Medical School

Seth MnookinProfessor of Science Writing and the Director of the Graduate Program in Science Writing atMcGovern Institute for Brain Research at MIT

4:30 PM–5:30 PM

Jun 5, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

Need for Speed: Responding to Influenza Pandemics

Room 251, Level 2

Speakers

Monique MansouraProject Leader, Global Health Security atMitre

Dr. Rick BrightDeputy Assistant Secretary for Preparedness and Response, Director of Biomedical Advances Research and Development Authority atU.S. Department of Health and Human Services (HHA)

Dr. Bruce GellinPresident atSabine Institute

David LoewExecutive Vice President, Head atSanofi Pasteur

Gordon NaylorPresident atSeqirus

Michael WatsonSVP Vaccine Partnerships & Health Impact atModerna Therapeutics

11:00 AM–12:00 PM

Jun 6, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

The Value of Addressing AMR

Room 251, Level 2

Speakers

Prof. Ian GreerVice President and Dean, Faculty of Biology Medicine and Health atUniversity of Manchester.

Prof. Colm LeonardClinical adviser atThe National Institute for Health and Care Excellence (NICE)

Dr. Evan LohChief Operating Officer, Chief Medical Officer atParatek

Mark Sculpher, PhDProfessor of Health Economics atUniversity of York

1:45 PM–2:45 PM

Jun 6, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

Preventing Resistance: The Role of Vaccines in AMR

Room 251, Level 2

Speakers

Alycia DraperVaccines Policy Lead atWellcome Trust

Tim CookeConsultant atNovadigm Therapeutics

Dr. Pierre MeulienExecutive Director atInnovative Medicines Initiative

Tania TeixeiraEMA Liaison Official at FDA atEuropean Medicines Agency

Jim WassilBusiness Unit Lead, Vaccines atPfizer

3:00 PM–4:00 PM

Jun 6, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

New Development Strategies for Vaccines and Therapeutics for the Developing World

Room 251, Level 2

Speakers

Amy FinanCEO atSABIN VACCINE INSTITUTE

Swati GuptaVice President, Research Integration & Innovation atInternational AIDS Vaccine Initiative

Penny Heaton, MDChief Executive Officer atThe Bill & Melinda Gates Medical Research Institute

David Mantus, PhDChief Development Officer atArsanis, Inc

Paul Stoffels, MDExecutive Vice President, Chief Scientific Officer atJohnson & Johnson

4:15 PM–5:15 PM

Jun 6, 2018

infectiousdisease_icon

Infectious Diseases & Vaccines

Fueling Antifungus Among Us: The Cost to Keep Up

Room 251, Level 2

Speakers

Cammy DuongDirector atMacDougall Biomedical Communications

Heather BehannaPrincipal of Private Equity atSofinnova Ventures

Alan Carr, PhDSenior Analyst atNeedham and Co.

Ciara KennedyPresident and CEO atAmplyx

Marco TagliettiPresident and CEO atScynexis, Inc.